|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.965 USD | 0.00% |
|
-2.15% | -66.40% |
| 07-08 | Seres Therapeutics Announces Early Clinical Data Showing Potential For SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis | CI |
| 07-08 | Seres Therapeutics, Inc. - Special Call |
| Market Cap | 48.08M 42.27M 39.35M 36.13M 67.85M 4.61B 68.75M 468M 183M 2.28B 180M 177M 7.87B | P/E 2026 * |
-0.66x | P/E 2027 * | -0.76x |
|---|---|---|---|---|---|
| Enterprise Value | 48.08M 42.27M 39.35M 36.13M 67.85M 4.61B 68.75M 468M 183M 2.28B 180M 177M 7.87B | EV / Sales 2026 * |
3.74x | EV / Sales 2027 * | 134x |
| Free-Float |
88.22% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Seres Therapeutics, Inc.
| 1 day | -0.20% | ||
| 1 week | -2.15% | ||
| Current month | -36.63% | ||
| 1 month | -35.82% | ||
| 3 months | -31.70% | ||
| 6 months | -67.62% | ||
| Current year | -66.40% |
| 1 week | 4.9 |  | 5.44 |
| 1 month | 4.9 | | 8.25 |
| Current year | 4.9 | | 16.42 |
| 1 year | 4.9 | | 29.98 |
| 3 years | 4.9 | | 105.8 |
| 5 years | 4.9 | | 233.8 |
| 10 years | 4.9 | | 770 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Kender
CEO | Chief Executive Officer | 70 | 01/03/2026 |
Matthew Henn
PSD | President | 51 | 01/03/2026 |
Ann Thorell
CEO | Chief Executive Officer | 58 | 31/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Richard Kender
CHM | Chairman | 70 | 01/03/2026 |
Eric Shaff
BRD | Director/Board Member | 50 | 14/01/2019 |
Dennis Ausiello
BRD | Director/Board Member | 80 | 31/03/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 08/07/26 | Free | Director | 6,500 | 0.0671% | ||
| 08/07/26 | Free | Director | 6,500 | 0.0671% | ||
| 08/07/26 | Free | Director | 6,500 | 0.0671% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -2.15% | -62.24% | -94.34% | 48.08M | |
| -1.82% | +4.80% | +54.32% | +68.36% | 57.28B | |
| -0.27% | +5.74% | +40.26% | +80.17% | 54.99B | |
| -0.86% | -0.56% | +4.59% | +421.67% | 23.18B | |
| +2.76% | -0.24% | -18.49% | -12.44% | 22.59B | |
| -1.13% | +4.54% | +22.73% | -8.06% | 20.46B | |
| +1.57% | +3.30% | +27.41% | -29.07% | 17.56B | |
| -0.10% | +5.57% | +38.63% | +565.16% | 15.67B | |
| +5.29% | 0.00% | +185.09% | +332.66% | 14.46B | |
| +1.27% | +1.06% | +26.42% | +186.33% | 13.92B | |
| Average | +0.64% | +0.77% | +31.87% | +151.04% | 24.01B | |
| Weighted average by Cap. | +0.08% | +1.93% | +40.00% | +139.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 12.86M 11.3M 10.52M 9.66M 18.15M 1.23B 18.38M 125M 48.85M 609M 48.27M 47.23M 2.1B | 358K 315K 293K 269K 505K 34.33M 512K 3.48M 1.36M 16.95M 1.34M 1.31M 58.59M |
| Net income | -70.97M -62.39M -58.08M -53.33M -100M -6.81B -101M -690M -270M -3.36B -266M -261M -11.62B | -99.82M -87.75M -81.69M -75.02M -141M -9.57B -143M -971M -379M -4.73B -375M -367M -16.34B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/07/26 | US$4.980 | +0.30% | 56,129 |
| 24/07/26 | US$4.965 | -5.07% | 84,528 |
| 23/07/26 | US$5.230 | -0.95% | 29,816 |
| 22/07/26 | US$5.280 | +0.57% | 28,772 |
| 21/07/26 | US$5.250 | +2.74% | 26,940 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MCRB Stock
Select your edition
All financial news and data tailored to specific country editions
